Valuation Northwest Biotherapeutics, Inc.

Stocks

Delayed OTC Markets Other stock markets 14:12:50 2026-07-17 EDT			5-day change	1st Jan Change
0.1590 ^USD	+3.58%		-10.67%	-30.51%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027
Market Cap ¹	364	358.4	254.6	-
Change	-	-1.53%	-28.97%	-
Enterprise Value (EV) ¹	364	358.4	350.7	379.5
Change	-	-1.53%	-2.16%	8.23%
P/E	-3.93x	-5.72x	-	-
PBR	-	-	-	-
PEG	-	0.1x	-	-
Capitalization / Revenue	-	-	-	6.54x
EV / Revenue	-	-	-	9.75x
EV / EBITDA	-	-	-	-
EV / EBIT	-	-	-5.21x	-8.01x
EV / FCF	-	-	-6.87x	-9.31x
FCF Yield	-	-	-14.5%	-10.7%
Dividend per Share ²	-	-	-	-
Rate of return	-	-	-	-
EPS ²	-0.07	-0.04	-	-
Distribution rate	-	-	-	-
Net sales ¹	-	-	-	38.93
EBITDA	-	-	-	-
EBIT ¹	-	-	-67.3	-47.4
Net income	-85.19	-61.48	-	-
Net Debt ¹	-	-	96.08	124.9
Reference price ²	0.2748	0.2288	0.1535	0.1535
Nbr of stocks (in thousands)	1,324,666	1,566,728	1,658,458	-
Announcement Date	3/31/25	4/15/26	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-	-	-	-	255M
WUXI APPTEC CO., LTD.	21.01x	6.5x	14.22x	1.51%	55.98B
ARGENX SE	32.14x	8.11x	25.17x	0.06%	53.69B
INSMED INCORPORATED	-42.14x	13.39x	-39.27x	-.--%	23.29B
BIONTECH SE	-18.24x	4.33x	-7.58x	-.--%	23.15B
WUXI BIOLOGICS (CAYMAN) INC.	25.76x	5.08x	13.4x	-.--%	20.58B
GENMAB A/S	24.7x	4.83x	15.74x	-.--%	17.76B
PHARMAESSENTIA CORPORATION	48.38x	19.66x	50.63x	0.08%	16.09B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-543.27x	38.19x	-1574.92x	-.--%	15.93B
EXELIXIS, INC.	17.5x	5.09x	11.83x	-.--%	14B
Average	-48.24x	11.69x	-165.64x	0.18%	24.07B
Weighted average by Cap.	-21.48x	9.97x	-93.55x	0.37%